NA
INZY

NewEdge Advisors’s Inozyme Pharma INZY Stock Holding History

NewEdge Advisors’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-381
Closed -$2.12K – 3564
2023
Q2 		$2.12K Buy
+381
New +$2.25K ﹤0.01% 3076

Other funds holding INZY

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NewEdge Advisors's INZY Position: Q3 2023 in Review

NewEdge Advisors sold out of Inozyme Pharma (INZY) in Q3 2023, closing a stake of 381 shares — an estimated $2.12K sold.

NewEdge Advisors first reported a position in INZY in Q2 2023 and held it in 1 quarter. The position peaked at $2.12K in Q2 2023. 77 funds tracked by Wall St. Rank hold INZY as of Q3 2023.

  • NewEdge Advisors reported no remaining Inozyme Pharma position as of Q3 2023 after selling out during the quarter.
  • NewEdge Advisors sold 381 Inozyme Pharma shares in Q3 2023, an estimated $2.12K.
  • NewEdge Advisors first reported a position in Inozyme Pharma in Q2 2023 and held it in 1 quarter.
  • NewEdge Advisors's Inozyme Pharma position peaked at $2.12K in Q2 2023.
  • 77 funds tracked by Wall St. Rank held Inozyme Pharma as of Q3 2023.

Based on NewEdge Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.